Fidec Corporation
11
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
18.2%
2 terminated/withdrawn out of 11 trials
80.0%
-6.5% vs industry average
91%
10 trials in Phase 3/4
75%
6 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants
Role: lead
A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2
Role: lead
Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants
Role: lead
A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine
Role: lead
A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
Role: lead
A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age
Role: lead
Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine
Role: lead
A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children
Role: lead
A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania
Role: lead
A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine
Role: lead
Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine
Role: lead
All 11 trials loaded